♦ D.V.M., National Taiwan University, Taiwan.
Advagene Biopharma Co., Ltd. has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. The development of products includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), therapeutic glycan conjugate vaccines, etc. Complete substance patents, application patents, and manufacturing process patents for product development have been filed and part of the patents have been issued in Europe, U.S., Japan, Taiwan, Russia, Australia, Canada and other countries.
In 2014, Taiwan Bio Industry Organization awarded “Detoxified LT Adjuvant Application and Platform Technology” the “Innovation of the Year”. Among selected indications, the nasal spray flu vaccine (LT-Flu) has completed the phase I human clinical trials, ultimately confirming its safety and efficacy. Data shows that LT-Flu vaccine is capable of enhancing not only Flu-specific IgG but also mucosal IgA titers. ADVAgene is in the process of entering clinical Phase II trials. In the future and subject to approval, Flu-LT will be supplied, not only to general public but also to the most needy elderly through health care providers, thereby providing a novel flu vaccine in a Influenza vaccine market worth more than $3 Billion each year.
Detoxified LT is also tested for the treatment of respiratory allergic diseases and expecting to file an IND in the final quarter of 2017. Detoxified LT has successfully received Taiwan, United States and Japan patents. The mechanism of action of detoxified LT has been verified. In animal studies, detoxified LT works as an immune-modulator that modulates immune responses between immune cells and allergens. These results indicate detoxified LT treatment may replace or reduce steroid usage in respiratory allergic patients. Phase-I/II studies in 2018 will be focused on Ragweed and house dust mites in allergic patients in US and Taiwan, respectively.
The trials on glycan detoxified LT conjugate vaccine have been shown to induce anti-glycan IgG antibody titers in humans. ADVAgene is also planning to enter this dynamic immunotherapy territory area and are looking forward to the relevant technical product development to expand the range and value of the company's product line. Ultimately we are aiming to provide unique new drugs to improve the quality of life and enhance human survival.